Once-Daily Oral Icotronkinra Outperforms Placebo in Ulcerative Colitis

FRIDAY, Oct. 23, 2026 -- For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according...